Back to results
US 12,564,643 B2Granted
Polymeric nanovaccines and uses thereof
AssigneeRamot at Tel-Aviv University Ltd.
InventorsRonit Satchi-Fainaro, Helena Florindo, Joao Conniot, Anna Scomparin
Life of this patent
Estimating the term…
Abstract
A polymeric nanoparticle is disclosed which comprises: (i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle; (ii) at least one adjuvant; and (iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle. Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.
Claims3
A polymeric nanoparticle comprising:
- (i) at least one disease-associated antigen which is capable of producing a T-cell response,
- (ii) at least one adjuvant;
- (iii) a dendritic cell targeting moiety which is attached to an outer surface of the nanoparticle comprising poly (lactic-co-glycolic acid) (PLGA), said dendritic cell targeting moiety comprising mannose (man), wherein 20% of the polymers of the nanoparticle are mannosylated, wherein said man is bound directly to said PLGA to form man-PLGA;
- (iv) a polynucleotide agent;
- and
- (v) d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS).
3 more elements
Dependencies are inferred from the claim text.